Detect Early-Stage Cancer With Greater Precision
Credit: iStock
Liquid biopsy is transforming cancer diagnostics, yet the challenge of detecting early-stage disease remains. Traditional methods often miss subtle but vital shifts in biomarker dynamics. Differentiating between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) offers a clearer epigenetic picture and can enhance diagnostic precision.
This poster explores how 6-base whole-genome sequencing of cfDNA boosts the sensitivity of liquid biopsy tests for early cancer detection.
Download this poster to discover:
- How 5mC and 5hmC outperform traditional biomarkers
- Why 5hmC provides critical insight for detecting early-stage tumors
- The potential of 6-base sequencing to advance liquid biopsy diagnostics
Brought to you by
Download the Poster for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version
